ClinicalTrials.gg
Not yet recruitingNCT05842746Updated May 6, 2023

Elemene Plus Stupp Protocol Versus Stupp Protocol Alone for Newly-diagnosed Glioblastoma

A Phase 2 interventional study of Elemene and Placebo in Glioblastoma, IDH-wildtype, sponsored by Peking Union Medical College Hospital. Not yet recruiting at 1 site in China. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2023-05-06.

Sponsored by Peking Union Medical College Hospital · Phase 2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
74
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 143 studies in Glioblastoma with a site in China — 74 open to participants now, 81 under way, 7 of them phase 3. Glioblastoma · China.

Planned enrollment
36th of 128
74 · median 36
Started
2023
with 13 others
Phase 2
35 of 143
17 open now
Primary completion
2026-12
later than 37 of 80 live
Registered
77th of 143
by date

Among the 143 studies in Glioblastoma with a site in China, this one is the 36th largest by planned enrollment of the 128 interventional ones that give a count, is one of 14 that started in 2023, is one of 35 in phase 2, reaches primary completion later than 37 of the 80 other live ones, and was the 77th registered.

Glioblastoma

2,137 studies on the registry are indexed under Glioblastoma; 465 are open to participants now.

Browse Glioblastoma studies →

Open to participants now

74 of the 143 studies in Glioblastoma with a site in China are open now. Recruiting first, the newest first:

69 more — sign in →

All 74 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 339 Glioblastoma studies recruiting now, 235 (69%) set no upper age limit and 65 (19%) stop at 75 or younger; 27 take children under 18; 14 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 143 studies in Glioblastoma with a site in China, or all of them as a file.
02

Study summary

The goal of this phase II randomized clinical trial is to compare the safety and efficacy of Elemene plus Stupp Protocol (the new protocol) and Stupp Protocol alone (the standard protocol) in patients with newly-diagnosed glioblastomas (ndGBMs). The main questions to answer are:

  • Whether the new treatment protocol (Elemene plus Stupp Protocol) is clinically safe for ndGBM patients.
  • Whether the new treatment protocol (Elemene plus Stupp Protocol) brings better survival benefits for ndGBM patients compared to the standard-of-care Stupp Protocol.

Study participants will be enrolled in 5 hospitals in China and randomly assigned to receive either the new protocol or the standard protocol. The overall survival (OS) rate in the 12th month, the progression-free survival (PFS) rate in the 6th month, OS, PFS, and adverse events assessed by the CTCAE (Common Terminology Criteria for Adverse Events) will be evaluated for all patients.

Read the detailed description

Glioblastoma (GBM) is a WHO grade 4 adult-type diffuse glioma and the most common malignant, primary brain tumor with a 5-year overall survival (OS) of only \~5% in real-world studies. The Stupp Protocol, consisting of fractionated focal irradiation in daily fractions of 2 Gy given 5 days/week for 6 weeks (a total of 60 Gy), plus concomitant daily temozolomide (TMZ, 75 mg/m2/day, 7 days/week from the first to the last day of radiotherapy) after maximal safe tumor resection, followed by six cycles of adjuvant TMZ (150-200 mg/m2/day for 5 days during each 28-day cycle), has been adopted as the standard of care for patients with newly-diagnosed GBMs (ndGBMs) since 2005.

However, there have been no other treatment modalities except for tumor treating fields (TTFields) that have brought survival benefits for ndGBM patients during the past two decades. Since TTFields therapy is super expensive (about 1 million yuan/0.15 million dollars per year) and fewer than 10% of ndGBM patients can afford it around the globe, the Stupp Protocol is still being used as the first-line and the most widely-adopted treatment option for ndGBM patients around the world.

Elemene, a Chinese anti-tumor medicine extracted from the plant Curcuma Wenyujin, has been isolated as a monomeric drug and has a broad-spectrum anti-tumor effect in various cancers, such as lung cancer, breast carcinoma, leukemia, and ovarian cancer. In recent years, its application in GBMs as revealed in the preliminary retrospective studies published in Chinese Journals and a few English Journals have shown survival benefits with acceptable toxicity. Elemene can pass through the blood-brain barrier because of its small molecular weight and lipid solubility and has synergistic anti-tumor effects with TMZ and radiotherapy for GBM patients. Several in vitro studies also have shown that Elemene could inhibit GBM cell proliferation, promote cell differentiation, and induce cancer cell apoptosis.

All these findings from the above studies have indicated the potential survival benefits of Elemene in treating ndGBMs. However, so far, no clinical trials have tested the efficacy and safety of the new treatment protocol (Elemene added to the Stupp Protocol) for ndGBMs compared with the conventional Stupp protocol.

In this study, the investigators aimed to launch a multi-center, phase II, randomized, controlled clinical trial to test the safety and efficacy of Elemene plus Stupp Protocol compared with Stupp Protocol alone for ndGBM patients.

03

Conditions studied

  • Glioblastoma, IDH-wildtype

Browse trials for

04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • newly-diagnosed supratentorial glioblastoma, IDH-wildtype, WHO grade 4
  • male or female adult patients \< 70 years old
  • performance status (KPS) score higher or equal to 60
  • a minimum of 12 weeks
  • adequate bone marrow function (white blood cell ≥ 2.0 × 10\^9/L, neutrophils ≥ 1.5 × 10\^9/L, ≥ 90 g/L, and ≥ 100 × 10\^9/L)
  • adequate hepatic function (direct and indirect bilirubin ≤ 1.5 mg/dL, and [ALT] and aspartate aminotransferase [AST] \< 4 times the )
  • adequate renal function (creatinine \< 80 umol/L)
  • adequate coagulation function ( [INR] ≤ 1.3)
  • voluntary to participate in this trial, complete all pre-specified treatment regimens, and complete required follow-up

Exclusion criteria

Exclusion Criteria:

  • unwilling to participate or accept the pre-specified treatment regimen and required follow-up schedule
  • prior treatment (surgery, radiotherapy, chemotherapy) for glioblastoma
  • pregnant or lactating patients
  • allergic to Elemene and its components
  • severe liver and kidney dysfunction, coagulation disorders, or decreased hematopoietic ability
  • serious infection
  • serious hyperlipidaemia
  • medical illness or psychosocial circumstance that may compromise participant safety
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
74 participants (estimated)

Study arms

  • Placebo comparator
    Stupp Protocol

    Patients receive maximal safe tumor resection, concurrent radiochemotherapy with TMZ, and adjuvant TMZ (the Stupp Protocol). Placebo that has the same appearance and flavor with Elemene is given 20ml orally, three times a day for 28 consecutive days (as one cycle) for 6 cycles, during the phase of adjuvant TMZ administration.

    Drug: Placebo

  • Experimental
    Ele-Stupp Protocol

    Patients receive maximal safe tumor resection, concurrent radiochemotherapy with TMZ, and adjuvant TMZ (the Stupp Protocol). Elemene is given 20ml:176mg orally, three times a day for 28 consecutive days (as one cycle) for 6 cycles, during the phase of adjuvant TMZ administration.

    Drug: Elemene

Interventions

  • Elemene of 20ml is given orally, three times a day, for 28 consecutive days (as a cycle), for 6 cycles.

  • DrugPlacebo

    Placebo (with the same appearance and flavor with Elemene) of 20ml is given orally, three times a day, for 28 consecutive days (as a cycle), for 6 cycles.

06

What researchers measure

Primary outcomes

  1. The overall survival (OS) rate in the 12th month (12m-OS)

    The rate of patients who are still alive in the 12th month after randomization

    Time frame: 12th month after randomization

Secondary outcomes

  1. The overall survival (OS)

    The survival time from randomization to death from any cause

    Time frame: From randomization to death, assessed up to 24 months

  2. The progression-free survival (PFS)

    The survival time from randomization to objective tumor progression or death

    Time frame: From randomization to objective tumor progression or death, assessed up to 24 months

  3. The progression-free survival (PFS) rate in the 6th month (6m-OS)

    The rate of patients who have no objective tumor progression in the 6th month after randomization

    Time frame: 6th month after randomization

  4. Adverse events

    Adverse events evaluated using the CTCAE version 4.03

    Time frame: From randomization to death, assessed up to 24 months

Other outcomes

  1. Subgroup analyses for primary and secondary outcomes

    Subgroups to be divided by sex, age, molecular alterations, KPS score, and extent of resection.

    Time frame: From randomization to death, assessed up to 24 months

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: Yes — Individual participant data (IPD) can be made available upon publication.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form

Time frame: Upon publication.

Access criteria: Via communication with the corresponding authors.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for May 2023; primary completion for Dec 2026, 43 months later.

Of 197 non-industry phase 2 interventional studies under Glioblastoma, half reached primary completion within 59 months of starting (the median), counting those still running; a quarter within 41 and three quarters within 88. This study's planned 43 months is below that.

Counting every sponsor, half of 248 studies reached it within 55 months; a quarter within 40 and three quarters within 87.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 9, 2023
First posted
May 6, 2023
StartEst.
May 2023
Primary completionEst.
Dec 2026
CompletionEst.
May 2027
Last update
May 6, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 6, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05842746
Responsible party
Sponsor
First posted
May 6, 2023
Start date
May 2023 (estimated)
Primary completion
Dec 2026 (estimated)
Completion
May 2027 (estimated)
Last update
May 6, 2023

Study contacts

Yu Wang, MD, PhD
Contact
ywang@pumch.cn
01069152530
Wenbin Ma, MD
study chair · Peking Union Medical College Hospital
Yu Wang, MD, PHD
principal investigator · Peking Union Medical College Hospital

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Apr 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Elemene

Start the discussion